Allergan PLC. (NYSE: AGN) and NephroGenex (OTCMKTS:NRXGQ) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Institutional & Insider Ownership

81.7% of Allergan PLC. shares are held by institutional investors. 0.4% of Allergan PLC. shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and target prices for Allergan PLC. and NephroGenex, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Allergan PLC. 0 7 11 0 2.61
NephroGenex 0 0 1 0 3.00

Allergan PLC. presently has a consensus price target of $245.00, indicating a potential upside of 40.14%. NephroGenex has a consensus price target of $17.50, indicating a potential upside of 624,900.00%. Given NephroGenex’s stronger consensus rating and higher probable upside, analysts clearly believe NephroGenex is more favorable than Allergan PLC..

Valuation and Earnings

This table compares Allergan PLC. and NephroGenex’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Allergan PLC. $14.57 billion 3.99 $14.97 billion ($22.50) -7.77
NephroGenex N/A N/A N/A ($2.32) 0.00

Allergan PLC. has higher revenue and earnings than NephroGenex. Allergan PLC. is trading at a lower price-to-earnings ratio than NephroGenex, indicating that it is currently the more affordable of the two stocks.

Dividends

Allergan PLC. pays an annual dividend of $2.80 per share and has a dividend yield of 1.6%. NephroGenex does not pay a dividend. Allergan PLC. pays out -12.4% of its earnings in the form of a dividend.

Profitability

This table compares Allergan PLC. and NephroGenex’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Allergan PLC. -47.27% 8.00% 4.45%
NephroGenex N/A -211.97% -105.90%

Volatility & Risk

Allergan PLC. has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, NephroGenex has a beta of -0.98, suggesting that its stock price is 198% less volatile than the S&P 500.

Summary

Allergan PLC. beats NephroGenex on 9 of the 13 factors compared between the two stocks.

Allergan PLC. Company Profile

Allergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.

NephroGenex Company Profile

NephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.